Navigation Links
AstraZeneca and Targacept Announce Top-Line Results from Phase IIb Study of AZD3480 in Alzheimer's Disease
Date:9/15/2008


WILMINGTON, Del., Sept. 15 /PRNewswire-FirstCall/ --

-- Results inconclusive, as primary outcome measure not statistically

significant for either donepezil or AZD3480; results impacted by

improvement in placebo group

-- Improvements shown on secondary outcome measures ADCS-CGIC and MMSE

-- Overall safety and tolerability profile comparable to placebo, with

fewer GI-related AEs than donepezil

-- Next steps include further analysis of full dataset and planned

discussions with leading medical experts

AstraZeneca (NYSE: AZN) and Targacept, Inc. today announced that results from the Phase IIb clinical trial of AZD3480 (TC-1734) conducted by AstraZeneca in mild to moderate Alzheimer's disease were inconclusive.

In the 12-week placebo-controlled study, known as the Sirocco trial, neither the active comparator donepezil nor AZD3480 met the trial's criteria for statistical significance on the primary outcome measure, ADAS-Cog (Alzheimer's Disease Assessment Scale -- Cognition Subscale.) Both results were impacted by an improvement in the placebo group.

At two of the three doses tested, AZD3480 showed an improvement on the secondary outcome measures ADCS-CGIC (Alzheimer's Disease Cooperative Study -- Clinical Global Impression of Change, a 7-point scale), a widely accepted measure of clinician assessment of change in patients' behavior and ability to function, and MMSE (Mini Mental State Examination, a 30-point scale), a quantitative cognition scale commonly used by neurologists in a clinical setting. Of the three AZD3480 doses, the middle dose performed best on both measures (0.5 point improvement, ADCS-CGIC and 0.9 point improvement, MMSE). Donepezil also sh
'/>"/>

SOURCE AstraZeneca
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds
2. AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six
3. Phase III Study of Abbotts Investigational TriLipix(TM) in Combination With AstraZenecas CRESTOR(R) Meets Primary Endpoints on Key Lipids
4. AstraZeneca Submits sNDA for NEXIUM(R) I.V. for Peptic Ulcer Bleed Indication
5. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
6. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines
7. Volcano Announces Participation in SATURN Clinical Trial Sponsored by AstraZeneca
8. AstraZeneca Submits an sNDA for SYMBICORT(R) for COPD Indication
9. AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression
10. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
11. New Analysis of METEOR Study Demonstrate Effects of AstraZenecas CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Bio-Holdings Ltd. (TASE: HDST, OTC: HADSY), a publicly ... property developed and owned by Hadassah University Hospital, ... center, today announced that its portfolio company, Cell ... Israeli Ministry of Industry and Commerce, Office of ... and advance clinical trials. Cell Cure,s development budget ...
(Date:5/23/2013)... May 23, 2013  Texas, premier physician associations today ... the survival tools they need to provide demonstrably better ... health care marketplace. "I am confident the ... practices," said Stephen L. Brotherton , ... Texas doctors are determined to make ...
(Date:5/23/2013)... , May 23, 2013  Net Medical Xpress ... telemedicine market, announced today the company has signed a ... staffing company based in Huntsville, AL ... specializes in the staffing and recruitment of telemedicine physicians. ... of the final agreement, which is expected by June ...
Breaking Medicine Technology:Hadasit Bio-Holdings Ltd. Portfolio Company - Cell Cure Neurosciences Ltd. Received Additional Government Support 2TMA Launches Physician Services Organization for Patient Care 2TMA Launches Physician Services Organization for Patient Care 3TMA Launches Physician Services Organization for Patient Care 4Net Medical Xpress Announces Acquisition of Telemedicine Staffing Company 2Net Medical Xpress Announces Acquisition of Telemedicine Staffing Company 3
... state,are invited to help advance research in women,s ... The registry, created by the Institute,for Women,s Health ... developed to encourage researchers to focus on women,s ... the chance to be part of,university-sponsored research studies ...
... 13 Raven,biotechnologies, inc., a privately held company ... therapeutics (MAbs) for cancer,today announced that it has ... lead,clinical product, in combination with gemcitabine in the ... Phase 2 Pancreatic Cancer Study will be conducted ...
Cached Medicine Technology:Women Invited to Join New Health Registry to Advance Research 2Raven Announces Initiation of a RAV12 Phase 2 Clinical Trial in Metastatic Pancreatic Cancer 2Raven Announces Initiation of a RAV12 Phase 2 Clinical Trial in Metastatic Pancreatic Cancer 3
(Date:5/24/2013)... (PRWEB) May 24, 2013 The ... of products used outside the central laboratory, by ... a healthcare practitioner or by consumers. This includes ... fertility and pregnancy, infectious and cardiovascular disease and ... such as critical care, surgical and emergency departments. ...
(Date:5/24/2013)... of its kind, Impacts World 2013 from May ... from politics, business and civil society to discuss ... research across sectors and scales. , Webcast of ... May 27th, 1pm to 1:55pm and opening plenary ... include: , Connie Hedegaard, EU Commissioner for ...
(Date:5/24/2013)... research presented today shows that formation of new neurons ... its importance in learning and remembering - could cause ... existing brain circuits. Drs. Paul Frankland and Sheena ... Toronto, argue this reorganization could have the positive effect ... capacity for new learning. These results were presented ...
(Date:5/24/2013)... The creative flair and design talent ... (PolyU)'s Institute of Textiles and Clothing (ITC) have won ... Show held on 22 May at The Mira Hong ... ITC design students, various knitwear producers and yarn suppliers, ... of four outfits from 20 graduating students majoring in ...
(Date:5/24/2013)... -- Nearly three out of four pregnant women ... but these issues don,t significantly affect their quality ... from Loyola University Medical Center in Maywood, Ill., ... physiological and hormonal changes that occur during pregnancy. ... can play a role. The study authors added ...
Breaking Medicine News(10 mins):Health News:Point of Care Diagnostics Market (POC) Analysis and 5 Year Forecast in New Research Report at ReportsnReports.com 2Health News:Point of Care Diagnostics Market (POC) Analysis and 5 Year Forecast in New Research Report at ReportsnReports.com 3Health News:New neuron formation could increase capacity for new learning, at the expense of old memories 2Health News:PolyU Stages Knitwear Fashion Show 2Health News:Bowel Issues Affect 3 Out of 4 Pregnant Women 2
... MSA ), the,global leader in the development, manufacture and ... announced today that it,will broadcast a third quarter 2007 ... 1, 2007 at 10:00 a.m. EDT. The call will,last ... have the opportunity to listen to,the conference call live ...
... therapies drugs developed to attack specific molecules in ... work well by themselves, increasingly researchers are finding that ... conventional therapies. , Reported today at the AACR-NCI-EORTC ... applications of new and existing drugs are offering new ...
... Pocket Expenses ... for Medical Foods, NOVATO, ... today that it has,provided a $250,000 grant to the National Organization ... patients with,phenylketonuria (PKU), a rare genetic metabolic disorder. Funds from this,new ...
... (OTC Bulletin,Board: NTRZ), a health science company and ... research and technology whose products include,food supplements and ... animals announced today that it has retained the ... an expanded,communications program among the investment community. ...
... have discovered a way to use a simple blood ... which gives little warning and is almost always fatal ... Public Library of Science (PLoS), represents the collaborative work ... Diagnostics. , TAAs occur in the part of the ...
... MADISON, N.J., Oct. 24 Quest Diagnostics,Incorporated (NYSE: ... diagnostic,testing, information and services, announced that for the ... operations was $150,million, or $0.77 per diluted share, ... in the third quarter of 2006. The third ...
Cached Medicine News:Health News:MSA Schedules Third Quarter Earnings Webcast 2Health News:Combination targets: some drugs may work best when they work together 2Health News:Combination targets: some drugs may work best when they work together 3Health News:Combination targets: some drugs may work best when they work together 4Health News:Combination targets: some drugs may work best when they work together 5Health News:Combination targets: some drugs may work best when they work together 6Health News:Combination targets: some drugs may work best when they work together 7Health News:BioMarin Provides Grant to NORD to Expand PKU Patient Support Services 2Health News:BioMarin Provides Grant to NORD to Expand PKU Patient Support Services 3Health News:BioMarin Provides Grant to NORD to Expand PKU Patient Support Services 4Health News:BioMarin Provides Grant to NORD to Expand PKU Patient Support Services 5Health News:NutraCea Appoints Financial Relations Board as New Investor Relations Firm 2Health News:NutraCea Appoints Financial Relations Board as New Investor Relations Firm 3Health News:A new key to detecting deadly aortic aneurysms 2Health News:Quest Diagnostics Reports Third Quarter Results 2Health News:Quest Diagnostics Reports Third Quarter Results 3Health News:Quest Diagnostics Reports Third Quarter Results 4Health News:Quest Diagnostics Reports Third Quarter Results 5Health News:Quest Diagnostics Reports Third Quarter Results 6Health News:Quest Diagnostics Reports Third Quarter Results 7Health News:Quest Diagnostics Reports Third Quarter Results 8Health News:Quest Diagnostics Reports Third Quarter Results 9Health News:Quest Diagnostics Reports Third Quarter Results 10Health News:Quest Diagnostics Reports Third Quarter Results 11Health News:Quest Diagnostics Reports Third Quarter Results 12Health News:Quest Diagnostics Reports Third Quarter Results 13Health News:Quest Diagnostics Reports Third Quarter Results 14Health News:Quest Diagnostics Reports Third Quarter Results 15
... the sounds you need to ... other body sounds while reducing ... Littmann Model 3000., ,With Ambient ... to 18 times amplification, and ...
CVC 123 is an assayed quality control material used for confirming the calibration and linearity of blood gas, electrolyte, and metabolite instrumentation....
... control material used for monitoring the performance of ... for specific use on Bayer analyzers that measure ... 270) and the AVOX Systems CO-Oximeters (4000 and ... the IRMA TRUpoint. CC 527 is available in ...
Equinox is a truly unique approach to cosmetic enhancement contact lenses and is worn as a conventional wear lens....
Medicine Products: